Outcome of Partial Pulpotomy in Permanent Mandibular Molars With Symptomatic Irreversible Pulpitis After Wound Lavage With Calcium Hypochlorite or Sodium Hypochlorite
Aperçu de l'étude
Statut
Description détaillée
The aim of this randomised control trial is to compare the effect of wound lavage using 2.5% Ca(OCl)₂ and 2.5% NaOCl on the outcome of partial pulpotomy in mature permanent mandibular molars with symptomatic irreversible pulpitis (SIP).
PICO P (Population) -Mature permanent mandibular molars with carious pulpal exposure and symptomatic irreversible pulpitis (SIP).
I (Intervention) - wound lavage using 2.5% Ca(OCl)₂ C (Comparison) - wound lavage using 2.5% NaOCl O (Outcome) -
- Assessment of clinical and radiographic success at 6 and 12 months of follow up.
- Assessment of OHRQoL and pain experience at baseline, post-operatively every 24 hours for 1 week and OHRQoL at 6 and 12 months.
In symptomatic irreversible pulpitis (SIP), bacterial invasion of pulp tissue is common, however the inflammation is usually confined to the area adjacent to the carious lesion. It has been suggested that removal of this affected pulp tissue segment and the surrounding infected dentin can help create an environment that promote pulpal healing.
Mechanical removal of the infected pulpal tissue can be most conservatively done through partial pulpotomy (PP) where a superficial coronal inflamed pulp tissue (2-3 mm) is amputated.
PP has been proven useful in cases of irreversible pulpitis with a high success rate .This procedure is advantageous as it preserves the coronal pulp tissue and allows physiologic dentine deposition in the cervical area.
In contrast to complete pulpotomy (CP), PP removes only the superficial coronal pulp tissue, which may increase the likelihood of leaving behind affected pulp tissue.This part of the pulp, if left behind, may affect the outcome of PP. Hence, lavage with antibacterial agents in such cases may help in dissolving and disinfecting the superficial layer of the pulp wound.
Sodium hypochlorite (NaOCl) is widely used in VPT due to its antimicrobial activity, tissue-dissolving ability, and haemostatic properties. However, concerns regarding cytotoxicity, collagen degradation, compromised resin bond strength due to interference in polymerisation of composite, and handling hazards remain.
Other lavage agents such as normal saline and chlorhexidine (CHX) have shown limitations, Success of DPC following pulp wound lavage with NaOCl and saline observed significantly lower pulp survival with saline as compared to NaOCl.
CHX also exhibits dose and time- dependent cytotoxicity on fibroblastic and osteoblastic cell lines , does not dissolve organic tissue and has allergic potential .
Calcium hypochlorite [Ca(OCl)₂] has been proposed as an alternative to NaOCl owing to its comparable antimicrobial efficacy, lower cytotoxicity, minimal collagen damage, and preservation of dentin mechanical properties.
Ca(OCl)2 also releases calcium ions, suggesting a potential to promote mineralisation, this may be particularly relevant in teeth with pulp necrosis and incomplete root formation, in which REPs are indicated.
Ca(OCl)2 at 1.5% caused less structural damage to apical papilla ex vivo than NaOCl at the same concentration and had a more favourable influence on the viability, proliferation and osteogenic differentiation of human apical papilla cells(hAPCs) in vitro. Moreover, it did not impair cell chemotaxis. These findings suggest that Ca(OCl)2 may offer biological advantages in regenerative endodontic procedures.
As an endodontic irrigant, Ca(OCl)2 demonstrated organic tissue dissolution capacity .
It also provides antimicrobial effects when used as an intracanal medication for regenerative endodontics procedures, or when added to endodontic sealers .
In addition to its effective tissue dissolution capacity, calcium hypochlorite exhibits advantages such as a higher available chlorine content and a broader spectrum of microbial action.
Ca(OCl)2 showed favourable outcomes in terms of cell migration, viability, and inflammatory response .
Although evaluated as an irrigant in root canal treatment, its role as a pulpal wound lavage agent during pulpotomy has not been investigated.
This trial would help formulate evidence based clinical guidelines regarding use of calcium hypochlorite as wound lavage agent during pulpotomy.
Type d'étude
Inscription (Estimé)
Phase
- N'est pas applicable
Contacts et emplacements
Coordonnées de l'étude
- Nom: Dr. Mayank Arora, MDS
- Numéro de téléphone: +918295964200
- E-mail: dr.arora002@gmail.com
Sauvegarde des contacts de l'étude
- Nom: Dr. Roshni N V, PG student
- Numéro de téléphone: +919048217877
- E-mail: roshninv1997@gmail.com
Lieux d'étude
-
-
Haryana
-
Rohtak, Haryana, Inde, 124001
- Recrutement
- PGIDS
-
Contact:
- Dr. Mayank Arora, MDS
- Numéro de téléphone: +918295964200
- E-mail: dr.arora002@gmail.com
-
Contact:
- Dr. Roshni N V, MDS
- Numéro de téléphone: +919048217877
- E-mail: roshninv1997@gmail.com
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte
Accepte les volontaires sains
La description
Inclusion Criteria:
- patients aged 18-40 years
- Mature permanent mandibular molars with extremely deep caries (caries penetrating the entire thickness of the dentine radiographically, without radiopaque zone separating lesion from the pulp) and clinical diagnosis of SIP with PAI score ≤ 2
- Periodontally healthy teeth (probing pocket depth ≤3 mm and mobility within normal limit)
- Patients having physical status of class 1 or 2 according to ASA classification
- Pulpal bleeding could be controlled within 10 min following pulp amputation
Exclusion Criteria:
- Non restorable teeth
- No pulp exposure even after complete caries excavation
- Necrotic or partially necrotic pulp upon exposure
- Presence of sinus tract or soft tissue swelling
- Radiographic signs of internal or external root resorption
- Pregnant women
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Tripler
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Partial pulpotomy using calcium hypochlorite as wound lavage agent
Partial pulpotomy will be performed using calcium hypochlorite as wound lavage agent ,after establishing a clinical diagnosis of symptomatic irreversible pulpitis i.e. if the tooth showed symptoms triggered and lingered by cold stimuli.
|
Following pulp exposure and clinical assessment of pulp health through bleeding, the patient was randomly assigned to 2.5% Ca(OCl)₂ group.Patients who did not exhibit pulp exposure after complete caries removal, or those with partially necrotic pulp, were excluded from the study. The pulp wound was irrigated with 5 ml 2.5% Ca(OCl)₂ for 30 s. Haemostasis was achieved by placing the cotton pellets soaked with 2.5% Ca(OCl)₂ over the pulpal wound for 2 min. This process was repeated further if required, for a maximum of 10 min. Patients whose bleeding could not be arrested within 10 min had to undergo CP or pulpectomy. ProRoot MTA will be placed to a thickness of 2-3 mm gently over the pulpal tissue, a layer of RMGIC will be placed over the MTA.Then the tooth will be permanently restored with composite resin. After restoration, a postoperative periapical radiograph will be taken using a digital imaging system for comparative evaluation after 6 months and 12 months follow up. |
|
Comparateur actif: Partial pulpotomy using sodium hypochlorite as wound lavage agent
Partial pulpotomy will be performed using sodium hypochlorite as wound lavage agent ,after establishing a clinical diagnosis of symptomatic irreversible pulpitis i.e. if the tooth showed symptoms triggered and lingered by cold stimuli.
|
Following pulp exposure and clinical assessment of pulp health through bleeding, the patient was randomly assigned to 2.5% NaOCl group.Patients who did not exhibit pulp exposure after complete caries removal, or those with partially necrotic pulp, were excluded from the study. The pulp wound was irrigated with 5 ml 2.5% NaOCl for 30 s. Haemostasis was achieved by placing the cotton pellets soaked with 2.5% NaOCl over the pulpal wound for 2 min. This process was repeated further if required, for a maximum of 10 min. Patients whose bleeding could not be arrested within 10 min had to undergo CP or pulpectomy. ProRoot MTA will be placed to a thickness of 2-3 mm gently over the pulpal tissue, a layer of RMGIC will be placed over the MTA.Then the tooth will be permanently restored with composite resin. After restoration, a postoperative periapical radiograph will be taken using a digital imaging system for comparative evaluation after 6 months and 12 months follow up. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Success rate at 12 months
Délai: 12 months
|
Criteria for success:- Clinical: 1. Absence of signs and symptoms of spontaneous pain or pain on stimulus and discomfort except for the first few days after treatment.
2. No tenderness to palpation or percussion and the tooth is functional.
3. Normal mobility and probing pocket depth.
4. Absence of associated soft tissue swelling, sinus or fistula.
Radiographic: - 1. Absence of any periapical or interradicular radiolucency.
2. Complete radiographic healing (PAI score 1 or 2 acc. to Ostravik et al).
3. Absence of internal and external root resorption Tooth will be considered successful when all the above parameters are met.
|
12 months
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Postoperative pain
Délai: Baseline and at 24 hours, Day 1, Day 2, Day 3, Day 4, Day 5, Day 6 and Day 7 after the treatment
|
Post Operative Pain To assess incidence and intensity of pain postoperatively at every 24 hours till 7 days using Visual analogue Scale of 0 to 100 millimeter line.
Score 0 means no pain and Score100 means maximum pain.
To assess incidence and intensity of pain postoperatively at every 24 hours till 7 days using Visual analogue Scale of 0 to 100 millimeter line.
Score 0 means no pain and Score 100 means maximum pain.
|
Baseline and at 24 hours, Day 1, Day 2, Day 3, Day 4, Day 5, Day 6 and Day 7 after the treatment
|
|
OHRQoL assessment
Délai: Baseline and at 24 hours, Day1,Day 2, Day 3, Day 4, Day 5, Day 6 and Day 7 after the treatment
|
OHIP-14 questionnare will be used to assess the quality of life.It consists of questionnaire in seven dimensions: functional limitation, physical pain, psychological discomfort, physical disability, psychological disability, social disability, and handicap.
It will be scored using a Lickert scale: never=0; hardly ever=1; occasionally=2; fairly often=3; very often=4.
Total score will be calculated ranging from 0-56, with higher score denoting the worst OHRQoL
|
Baseline and at 24 hours, Day1,Day 2, Day 3, Day 4, Day 5, Day 6 and Day 7 after the treatment
|
Collaborateurs et enquêteurs
Les enquêteurs
- Chercheur principal: Dr Mayank Arora, MDS, PGIDS, Rohtak, 124001
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Autres numéros d'identification d'étude
- Roshni N V
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .